hVIVO (LON:HVO) Stock Price Down 6.8% - Should You Sell?

hVIVO plc (LON:HVO - Get Free Report) shares fell 6.8% on Thursday . The company traded as low as GBX 19 ($0.24) and last traded at GBX 19.10 ($0.24). 2,518,262 shares traded hands during trading, a decline of 26% from the average session volume of 3,389,765 shares. The stock had previously closed at GBX 20.50 ($0.25).

hVIVO Price Performance

The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The firm's fifty day moving average is GBX 23.39 and its two-hundred day moving average is GBX 26.71. The company has a market cap of £129.95 million, a P/E ratio of 636.67 and a beta of 0.97.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.